Galectin Therapeutics' CMO Khurram Jamil Buys Company Shares
Khurram Jamil, Galectin Therapeutics' Chief Medical Officer, acquired 4,570 shares.
Key Points
- Khurram Jamil, the Chief Medical Officer at Galectin Therapeutics, bought 4,570 shares at $2.37 each on June 26, 2026.
- Shares of Galectin Therapeutics traded at $4.64 on Wednesday with a market cap of approximately $328.6 million.
- HC Wainwright & Co. reiterated a 'buy' rating with an $11 price target on June 23, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Khurram Jamil, Chief Medical Officer of Galectin Therapeutics Inc. (NasdaqCM: GALT), bought 4,570 shares of the company on June 26, 2026. The shares were purchased at an average price of $2.37, totaling approximately $10,814. This insider purchase was not part of a pre-planned trading program.
Insider Buying and Selling at Galectin Therapeutics Inc.
Alongside Khurram Jamil's purchase, other insider transactions were reported. Harold Shlevin bought 22,268 shares at $1.23 each on June 29, 2026, while also selling 22,268 shares at $5.04 in a planned transaction. Khurram Jamil also executed additional transactions on June 29, selling shares at $5.04 as part of a planned trade.
Galectin Therapeutics Inc. Stock Up 17.5%
Shares of Galectin Therapeutics traded near $4.64 on Wednesday. The company has a market capitalization of about $328.6 million. Galectin has no meaningful forward P/E ratio due to its lack of profitability, with a 52-week range between $2.03 and $7.13. Its 50-day moving average is $2.53, while the 200-day average stands at $3.72. The company's current ratio is 2.15, and its quick ratio is 1.93.
$GALT stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 23, 2026, HC Wainwright & Co. reiterated its 'buy' rating for Galectin Therapeutics, setting a price target of $11. This reflects confidence in the company's prospects despite its current financial metrics. The consensus remains positive with a single analyst recommending a 'buy' and a mean target price of $11.
About Galectin Therapeutics
Galectin Therapeutics Inc. is a biotechnology company based in Norcross, Georgia. It focuses on developing treatments for fibrotic diseases and cancer. The company's main product candidate, belapectin, is a galectin-3 inhibitor currently in Phase 2 clinical trials for patients with advanced fibrosis and cirrhosis. Led by CEO Joel Lewis, the company operates with a small team of nine employees.
Bottom Line
Khurram Jamil's purchase of Galectin Therapeutics shares adds a layer of interest for investors tracking insider activities. While the company's financials show challenges typical of a clinical-stage biotech firm, analysts maintain a positive outlook. Investors often watch insider transactions like these for signals of confidence in the company's potential growth.
Get Galectin Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $GALT, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.